You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 25, 2025

CLINICAL TRIALS PROFILE FOR ADAPALENE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ADAPALENE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial TypeTrial IDTitleStatusSponsorPhaseStart DateSummary
New Formulation NCT03615768 ↗ A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris Completed Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Limited Phase 3 2018-08-14 This is a study to see if Adapalene-Clindamycin Combination Gel is effective and safe in the treatment of acne vulgaris, compared to adapalene gel alone and clindamycin gel alone. Adapalene and clindamycin have been reported to have a better effect in acne treatment when used together. This new formulation is also easier to use as it combines two products into a single gel and only needs to be used once a day.
New Formulation NCT03615768 ↗ A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris Completed Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. Phase 3 2018-08-14 This is a study to see if Adapalene-Clindamycin Combination Gel is effective and safe in the treatment of acne vulgaris, compared to adapalene gel alone and clindamycin gel alone. Adapalene and clindamycin have been reported to have a better effect in acne treatment when used together. This new formulation is also easier to use as it combines two products into a single gel and only needs to be used once a day.
New Formulation NCT03615768 ↗ A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne Vulgaris Completed Lee's Pharmaceutical Limited Phase 3 2018-08-14 This is a study to see if Adapalene-Clindamycin Combination Gel is effective and safe in the treatment of acne vulgaris, compared to adapalene gel alone and clindamycin gel alone. Adapalene and clindamycin have been reported to have a better effect in acne treatment when used together. This new formulation is also easier to use as it combines two products into a single gel and only needs to be used once a day.
>Trial Type>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

All Clinical Trials for ADAPALENE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00151541 ↗ A Phase 3 Study to Compare the Safety and Efficacy of 5% Dapsone Topical Gel, (DTG) Twice Daily in Combination With Once Daily Vehicle Control, Adapalene Gel 0.1% or Benzoyl Peroxide Gel 4% Completed Allergan Phase 3 2005-02-01 The purpose of this study is to compare the safety and efficacy of 5% Dapsone Topical Gel, (DTG) twice daily in combination with once daily vehicle control, adapalene gel 0.1% or benzoyl peroxide gel 4%. The second objective of the study is to determine dapsone exposure after co-administration of DTG 5% with vehicle control, adapalene or benzoyl peroxide gel.
NCT00160394 ↗ Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed GlaxoSmithKline Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
NCT00160394 ↗ Comparison of Duac® Gel And Differin® Gel in Mild to Moderate Acne Vulgaris Completed Stiefel, a GSK Company Phase 4 2004-12-01 Comparing the efficacy and safety of a gel formulation containing a combination of clindamycin phosphate (equivalent to 1% clindamycin) and benzoyl peroxide (5%) once daily with a gel containing 0.1% adapalene once daily in the treatment of acne vulgaris of mild to moderate severity.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for ADAPALENE

Condition Name

591200102030405060Acne VulgarisAcnePhotoaging[disabled in preview]
Condition Name for ADAPALENE
Intervention Trials
Acne Vulgaris 59
Acne 12
Photoaging 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

720010203040506070Acne VulgarisAtrophySkin Manifestations[disabled in preview]
Condition MeSH for ADAPALENE
Intervention Trials
Acne Vulgaris 72
Atrophy 2
Skin Manifestations 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ADAPALENE

Trials by Country

+
Trials by Country for ADAPALENE
Location Trials
United States 224
Canada 30
Brazil 12
India 7
Germany 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for ADAPALENE
Location Trials
Texas 21
North Carolina 15
California 15
Florida 13
Pennsylvania 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ADAPALENE

Clinical Trial Phase

54.0%34.9%11.1%005101520253035Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for ADAPALENE
Clinical Trial Phase Trials
Phase 4 34
Phase 3 22
Phase 2 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

87.1%7.1%5.7%00102030405060CompletedUnknown statusNot yet recruiting[disabled in preview]
Clinical Trial Status for ADAPALENE
Clinical Trial Phase Trials
Completed 61
Unknown status 5
Not yet recruiting 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ADAPALENE

Sponsor Name

trials024681012141618Galderma R&DGaldermaGalderma Laboratories, L.P.[disabled in preview]
Sponsor Name for ADAPALENE
Sponsor Trials
Galderma R&D 17
Galderma 17
Galderma Laboratories, L.P. 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

74.0%26.0%00102030405060708090100IndustryOther[disabled in preview]
Sponsor Type for ADAPALENE
Sponsor Trials
Industry 91
Other 32
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Adapalene: Clinical Trials, Market Analysis, and Projections

Introduction to Adapalene

Adapalene, a naphthoic-acid derivative, is a topical retinoid widely used in the treatment of acne vulgaris and other dermatological conditions. Its unique properties make it an effective and well-tolerated option for patients.

Clinical Trials and Efficacy

Maintenance Therapy with Adapalene

A significant clinical trial demonstrated the efficacy of adapalene gel 0.1% as a maintenance therapy for acne vulgaris. In this study, subjects who had shown at least a 50% improvement from baseline after a 12-week treatment with either adapalene plus doxycycline or doxycycline plus gel vehicle were randomized to receive adapalene gel 0.1% or gel vehicle for an additional 16 weeks. The results showed that adapalene maintained superior efficacy compared to the vehicle, with significantly lower total, inflammatory, and noninflammatory lesion counts at the end of the 16-week period[1].

Comparison with Tretinoin

Several pivotal clinical trials have compared the efficacy and tolerability of adapalene with tretinoin, another common topical retinoid. These studies have consistently shown that adapalene gel 0.1% and solution 0.1% are at least as effective as tretinoin gel 0.025%, with superior local tolerability. Adapalene cream 0.1% also demonstrated significant efficacy over vehicle, with response rates comparable to those of the gel and solution formulations. The superior tolerability and rapid onset of clinical effect make adapalene a valuable addition to acne treatments[3].

Adapalene-Clindamycin Combination Gel

A recent Phase III clinical trial evaluated the efficacy of an adapalene 0.1%-clindamycin 1% combination gel compared to adapalene gel 0.1% and clindamycin gel 1% monotherapies. The results indicated that the combination gel was well-tolerated and demonstrated superior efficacy, with a significant reduction in total lesion count and a higher percentage of patients achieving at least a 2-grade improvement in the Investigator's Global Assessment (IGA) at week 12[4].

Market Analysis

Market Size and Growth

The adapalene drugs market is driven by several key factors, including the growing prevalence of acne, increasing awareness about skincare, and advancements in drug formulations. The market is expected to grow significantly over the next few years, with projections indicating a robust expansion in the global adapalene market from 2025 to 2030[2].

Market Segmentation

The adapalene market is segmented by product type (cream, gel, lotion), application (acne vulgaris, dark spots, psoriasis), distribution channel, patient demographics, and end-user. The gel formulation remains one of the most popular due to its efficacy and tolerability. The market also sees potential in targeting aging populations for anti-aging effects and in expanding product lines to include various formulations[2][5].

Key Market Players

Major companies contributing to the growth of the adapalene market include Galderma Laboratories, L.P., Allergan plc, Bausch Health Companies Inc., Perrigo Company plc, and several others. These companies are adopting various strategies such as collaborations, new product innovations, and technological advancements to stay competitive in the market[5].

Market Drivers

  • Growing Prevalence of Acne: The increasing incidence of acne among teenagers and young adults is a significant driver of the market.
  • Expanding Dermatology Services: The growth in dermatology clinics and professional skincare services amplifies prescriptions for adapalene products.
  • E-commerce Platforms: The widespread distribution and visibility of adapalene products through e-commerce platforms have boosted market demand[2].

Market Restraints

  • Supply Chain Disruptions: Overcoming supply chain disruptions affecting the availability of key components for adapalene drugs is a significant challenge.
  • Building Healthcare Provider Trust: Addressing criticisms and building trust among healthcare providers in prescribing adapalene drugs is crucial for market growth[2].

Market Projections

Future Growth Opportunities

The adapalene market is poised for significant growth, driven by several opportunities:

  • Targeting Aging Populations: Adapalene products focusing on wrinkle and fine line reduction are expected to gain traction.
  • E-commerce Expansion: Direct sales to consumers through e-commerce platforms offer substantial growth potential.
  • Increasing Skincare Awareness: Growing consumer awareness about skincare, especially in urban populations, is expected to drive demand[2][5].

Geographical Expansion

The market is expected to expand in emerging markets where skincare awareness is increasing. Strategic partnerships with dermatologists and enhanced digital marketing efforts are recommended to capitalize on these opportunities[2].

Consumer Satisfaction and Tolerability

Clinical trials have consistently shown that adapalene is well-tolerated and highly effective. In one study, a significant percentage of subjects receiving adapalene maintenance therapy were "very satisfied" or "satisfied" with the treatment effectiveness and overall maintenance treatment, compared to those receiving the vehicle[1].

Key Takeaways

  • Efficacy in Clinical Trials: Adapalene has demonstrated superior efficacy in maintaining acne treatment outcomes and in combination with clindamycin.
  • Market Growth Drivers: Growing acne prevalence, expanding dermatology services, and e-commerce platforms are key drivers.
  • Market Restraints: Supply chain disruptions and building healthcare provider trust are significant challenges.
  • Future Opportunities: Targeting aging populations, e-commerce expansion, and increasing skincare awareness are potential growth areas.
  • Consumer Satisfaction: Adapalene is well-tolerated and highly effective, leading to high consumer satisfaction.

FAQs

What is adapalene and how is it used?

Adapalene is a topical retinoid used primarily for the treatment of acne vulgaris. It is available in various formulations such as gel, cream, and lotion.

What are the key findings from clinical trials on adapalene?

Clinical trials have shown that adapalene is effective in maintaining acne treatment outcomes, has superior local tolerability compared to tretinoin, and is highly effective when combined with clindamycin.

What are the main drivers of the adapalene market?

The main drivers include the growing prevalence of acne, expanding dermatology services, and the growth of e-commerce platforms.

What challenges does the adapalene market face?

The market faces challenges such as supply chain disruptions and the need to build trust among healthcare providers.

What are the future growth opportunities for the adapalene market?

Future growth opportunities include targeting aging populations for anti-aging effects, expanding through e-commerce platforms, and increasing penetration in emerging markets.

Sources

  1. JAMA Dermatology: "Adapalene Gel, 0.1%, as Maintenance Therapy for Acne Vulgaris"[1]
  2. 360iResearch: "Adapalene Drugs Market Size & Share 2025-2030"[2]
  3. PubMed: "Pivotal clinical trials of adapalene in the treatment of acne"[3]
  4. PubMed: "A Randomized, Controlled, Assessor-Blind, Phase III Clinical Trial"[4]
  5. OpenPR: "Global Adapalene Market Outlook Opportunities and Innovations Till 2032"[5]

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.